Wellington Shields Capital Management LLC Sells 2,636 Shares of Johnson & Johnson $JNJ

Wellington Shields Capital Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 12.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 18,648 shares of the company’s stock after selling 2,636 shares during the period. Wellington Shields Capital Management LLC’s holdings in Johnson & Johnson were worth $2,849,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in JNJ. Machina Capital S.A.S. grew its holdings in Johnson & Johnson by 115.6% during the 2nd quarter. Machina Capital S.A.S. now owns 31,328 shares of the company’s stock worth $4,785,000 after acquiring an additional 16,798 shares during the last quarter. Tsfg LLC grew its stake in shares of Johnson & Johnson by 17.9% during the second quarter. Tsfg LLC now owns 3,107 shares of the company’s stock valued at $475,000 after purchasing an additional 472 shares during the last quarter. Intellectus Partners LLC increased its holdings in shares of Johnson & Johnson by 0.8% in the second quarter. Intellectus Partners LLC now owns 9,938 shares of the company’s stock valued at $1,518,000 after purchasing an additional 75 shares in the last quarter. Telos Capital Management Inc. lifted its holdings in Johnson & Johnson by 1.0% during the 2nd quarter. Telos Capital Management Inc. now owns 48,926 shares of the company’s stock worth $7,473,000 after buying an additional 467 shares in the last quarter. Finally, State of Michigan Retirement System lifted its holdings in Johnson & Johnson by 0.3% during the 2nd quarter. State of Michigan Retirement System now owns 680,867 shares of the company’s stock worth $104,002,000 after buying an additional 1,800 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. UBS Group raised their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Finally, Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.0%

Shares of Johnson & Johnson stock opened at $189.02 on Monday. The company has a market capitalization of $455.40 billion, a P/E ratio of 18.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The business has a 50-day moving average of $183.28 and a two-hundred day moving average of $167.75. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.